Hims and Hers Health's rollout of a compounded version of Wegovy has triggered investor unease, with the stock dropping 8.7% in early trading. The move raises concerns over regulatory compliance and competition in the weight-loss drug market.
- Hims and Hers Health (HIMS) launched a compounded semaglutide pill at $199/month, undercutting Novo Nordisk’s Wegovy priced at $1,349.
- The stock fell 8.7% in pre-market trading on February 5, 2026, amid regulatory and market concerns.
- FDA has warned against using compounded drugs for chronic conditions, citing safety, consistency, and dosing risks.
- Analysts project compounded semaglutide could capture 12%–15% of the U.S. weight-loss drug market within six months.
- Major insurers may restrict coverage for compounded versions, impacting patient access and reimbursement.
- Regulatory scrutiny is expected to intensify, with potential oversight of Hims and Hers’ compounding practices
Hims and Hers Health Inc. (HIMS) saw its shares decline sharply on February 5, 2026, after announcing the launch of a compounded formulation of semaglutide, the active ingredient in Novo Nordisk’s Wegovy. The company began offering the pill through its pharmacy platform at a price point of $199 per month, significantly below the commercial Wegovy price of $1,349. This development has prompted immediate market reaction, with HIMS trading down 8.7% in pre-market sessions and a broader pullback in health tech stocks. The launch marks a strategic shift for Hims and Hers, which has increasingly focused on accessible weight-loss therapies. By using compounded semaglutide, the company circumvents direct licensing agreements with pharmaceutical manufacturers, but faces growing regulatory uncertainty. The U.S. Food and Drug Administration has repeatedly cautioned against the use of compounded drugs for chronic conditions like obesity, citing concerns over consistency, safety, and dosing accuracy. The move also intensifies competition in a market dominated by Novo Nordisk and Eli Lilly, both of which report strong sales from their GLP-1-based obesity treatments. Analysts note that Hims and Hers’ compounded product could capture an estimated 12% to 15% of the U.S. weight-loss medication market within six months, based on current adoption trends. However, the lack of long-term clinical data for compounded formulations raises risks for both patients and insurers. Reimbursement challenges are expected, with major payers such as UnitedHealthcare and Aetna signaling potential restrictions on coverage for non-FDA-approved compounded drugs. The ripple effects extend beyond HIMS. Shares of private compounding firms and telehealth platforms with similar offerings have also declined, reflecting broader investor caution. Regulatory bodies are expected to review Hims and Hers' practices in the coming weeks. The company maintains that its compounding process follows state pharmacy board standards and that all formulations are prepared under strict quality controls.